Skip to Content
Merck
  • Cost-effectiveness and quality of life associated with heavy menstrual bleeding among women using the levonorgestrel-releasing intrauterine system.

Cost-effectiveness and quality of life associated with heavy menstrual bleeding among women using the levonorgestrel-releasing intrauterine system.

International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics (2011-01-29)
Paul D Blumenthal, Lindsey Dawson, Ritva Hurskainen
ABSTRACT

To review the literature for economic and health-related quality of life outcomes data associated with the use of the levonorgestrel-releasing intrauterine system (LNG-IUS) in the management of heavy menstrual bleeding. We searched the MEDLINE and EMBASE databases simultaneously using the Ovid interface to review the literature in a systematic manner for economic and health-related quality of life outcomes data associated with the use of the LNG-IUS in women with heavy menstrual bleeding. Articles were then selected for further review based on the relevance of their titles and/or abstracts. We identified 17 articles for inclusion in this review. Treating heavy menstrual bleeding with the LNG-IUS was found to be cost-effective in various countries and settings. Moreover, irrespective of the measuring instrument used, health-related quality-of-life outcomes were found to be improved to a degree similar to that achieved with endometrial ablation or hysterectomy. In some cases, the LNG-IUS appeared to be more effective and less costly than the surgical options. The LNG-IUS is a cost-effective treatment option for heavy menstrual bleeding when pharmacologic treatment is indicated.

MATERIALS
Product Number
Brand
Product Description

Levonorgestrel, European Pharmacopoeia (EP) Reference Standard
USP
Levonorgestrel, United States Pharmacopeia (USP) Reference Standard
Supelco
D(−)-Norgestrel, analytical standard
Levonorgestrel for system suitability 2, European Pharmacopoeia (EP) Reference Standard